Role of Device Therapy in FMR: Challenges and Opportunities

Slides:



Advertisements
Similar presentations
Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
Advertisements

Percutaneous mitral valve repair using the MitraClip® device (e-valve)
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
STICH Mitral Regurgitation Subanalysis Objective Examine the relationship of mitral regurgitation (MR) severity and survival and compare outcomes in patients.
PERCUTANEOUS MANAGEMENT OF MITRAL REGURGITATION
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
1 Investigational Device only in the U.S. Not available for sale in the U.S. ACCESS EU – ESC 2012 European Society of Cardiology Congress 2012 Munich,
©2015 MFMER | Robotic Repair of Simple vs. Complex Degenerative Mitral Valve Disease Clinical and Echocardiographic Outcomes During Mid-Term.
Department of Surgery, University of Pennsylvania Health System Which Operation is Best for Severe Ischemic MR: Repair or Replace? Michael Acker William.
Disclosure Statement of Financial Interest Saibal Kar, MD, FACC
Mitral Regurgitation. Abnormalities of the Mitral Valve Valve Leaflets Chordae Tendineae Papillary Muscles Mitral Annulus.
CARILLON™ Mitral Annuloplasty Device European Union Study Cardiac Dimensions ® CARILLON ™ Mitral Contour System ™
Adult Cardiac Valve Disease Marvin D. Peyton, M.D. Thoracic and Cardiovascular Surgery University of Oklahoma Health Sciences Center.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
+ Mitral Valve Prolapse A Surgeon’s Perspective Charles Anderson, M.D. Saint Joseph’s Hospital of Atlanta.
UNIVERSITA' CAMPUS BIO-MEDICO DI ROMA Via Álvaro del Portillo, Roma - Italia Antonio Nenna, MD Department of Cardiovascular.
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
MitraClip Mitral Valve Repair System Abbott Vascular MitraClip Mitral Valve Repair System Abbott Vascular Alexandra Camesas & Nathan Kukowski Biomaterials.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Primary Mitral Regurgitation Degenerative Mitral Valve Disease
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
Disclosure Statement of Financial Interest
Transcatheter Mitral Valve Replacement
Tendyne Design Features and Clinical Update
Device Navigation Leaflet Capture Distal tip Saddle CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
From Mitral Repair to Replacement
Jeff Macemon MBChB, PDMSM Advanced Trainee, CTS
CTSN Trials of Mitral Valve Repair and Replacement
on behalf of the EVEREST Investigators
Cardiovacular Research Technologies
Management of mitral regurgitation. See legend for Fig
Cardiovascular Research Technologies
Mitral Regurgitation: Epidemiology, Pathophysiology and When to Repair
Cardiothoracic Surgery
University of Pennsylvania Philadelphia
Functional MR: When to Intervene
Updates From NOTION: The First All-Comer TAVR Trial
A report from the STS/ACC TVT Registry
Possible Approval Pathways for Mitral Valve Device Therapies FDA View
Mayra Guerrero, MD, FACC, FSCAI
Percutaneous Treatment for Functional Mitral Regurgitation Using The CARILLON ® Mitral Contour System™ Steven L. Goldberg, MD Director, Cardiac Cath.
The CARILLON: Device Iteration, New Data and New Trials
University of Cincinnati Medical Center
Is There a Need to Address AF in patients Undergoing Valve Surgery?
First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus™ Aortic Valve Replacement System: Results From the REPRISE I.
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
Structural and Functional Mitral Regurgitation:
Giuseppe Tarantini MD, PhD
Washington Hospital Center
How I treat Functional Mitral Regurgitation: The Surgeon’s perspective
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
TAVI „Catch me if you can!“
Early Feasibility Studies Investigator Perspective
Transcatheter Mitral Valve Implantation
Surgical Mitral Valve Repair: What is the Gold Standard?
Edward Howard MBChB(Hons) PhD Robert Lager MD Augusto Pichard MD
EVEREST II 5-Year Report and Beyond
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
Timing of Intervention in Mitral Stenosis
UNCERTAINTY OF RISK: THE CASE OF THE TRICUSPID DEVICES
James Hermiller, MD, FACC, FSCAI St Vincent Hospital, Indianapolis, IN
Niv Ad, MD Chief, Cardiac Surgery Inova Heart and Vascular Institute
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
MitraClip: A Therapeutic Solution for Patients with Severe MR – Not a Candidate for Surgery Brij Maini MD, FACC Regional Medical Director of Transcatheter.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Cardiovacular Research Technologies
Nishith Patel Waikato Cardiothoracic Unit
Ischemic Mitral Regurgitation
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Role of Device Therapy in FMR: Challenges and Opportunities Ori Ben-Yehuda, MD, FACC Clinical Trials Center Cardiovascular Research Foundation & Columbia University

I have no relevant financial relationships ORI BEN-YEHUDA, MD   I have no relevant financial relationships

FMR: More complicated than AS

Spectrum of Mitral Regurgitation Mitral valve Left Atrium Chordae Tendnae Functional Mitral Regurgitation (FMR) Left ventricle Papillary muscles Degenerative Mitral Regurgitation (DMR) LV Dysfunction Dilated Annulus (Non-ischemic or ischemic dilated cardiomyopathy) LA Dysfunction Dilated Annulus (Chronic atrial fibrillation, hypertension) Etiologies: Advanced Barlow’s Disease Fibroelastic deficiency Leaflet prolapse due to: Leaflet deformities or lesions Ruptured/ elongated chordae Papillary muscle rupture Etiologies Loss of leaflet coapation due to: annular enlargement Papillary muscle displacement causing leaflet tethering/tenting Benjamin MM et al. Curr Cardiol Rep 2014;16:517

Functional MR: Role of Tethering Levine et al. Curr Cardiol Rep 2002;4:125-9

CTSN: MR Recurrence with Repair N Engl J Med 2016; 374:344-353

Transcatheter Valve Implanation (Piazza. PCR London Valve)

The Challenges with TMVR for FMR LV Dysfunction Advanced stage of disease- very high risk Are we selecting patients that are too advanced? Complex anatomy- D shaped annulus Risk of PVL Sizing Low flow compared with Aortic Valve- risk of thrombosis LVOT Obstruction Conduction system issues, coronary risk

Transcatheter Mitral Valve Repair: Many Options Leaflet repair MitraClip Pascal Percutaneous Annuloplasty Coronary sinus annuloplasty Carillon Direct annuloplasty Cardioband Mitralign Millipede MVRx Basal ventriculoplasty GDS Chordal replacement NeoChord Harpoon

EVEREST II: 5 year results

EVEREST II: MR Recurrence but good functional outcome Mitral Regurgitation NYHA Class Feldman T et al. JACC 2015

Carillion Cardiac Dimension Indirect annuloplasty with nitinol device anchored into the coronary sinus to reduce annulus dimensions Transgiugular approach 500 pts treated for commercial use 66 pts implanted in trial FMR Safe (Death @30d 0% device related) Results @12 mo 1 grade of MR reduction 1 NYHA Class improvement (from III to II)

Valtech Cardioband Direct annuloplasty with supra annular fixation of a band with anchors Transseptal approach ~100 pts treated FMR Death @30d 4% Effective significant reduction of septo lateral dimension average up to 30% significant MR reduction < 2 in 92% @discharge Sustained results @12 mo MR < 2, 91% NYHA I/II, 70%

Cardioband Study Demographics (N=54) No. (%) or Mean Variable 71 ± 8 Age (years) Male 41 Female 13 Gender 7 (1-33) Euroscore II (%) 82 Baseline NYHA Class of III or IV (%) 33 21 Ischemic Non Ischemic 61 ± 6 LVEDD (mm) AvgSD 33 ± 11 EF (%) AvgSD 18 (32%) 11 (20%) 41 (74%) 13(23%) Prev CABG COPD Moderate to Severe Renal Failure Severe Pulmonary Hypertension Afib

Reported Major Safety Events at 30 Days 30 Day Events* Patients Experiencing Event, # (%) All Patients N=54 Death 2 (3.7%) Hemorrhagic Stroke** 1 (1.9%) Need for elective Mitral Operation** Ischemic attack Major Bleeding Complications Renal Failure Myocardial Infarction 0 (0%) Respiratory Failure Cardiac Tamponade * VARC Guidelines (European Heart Journal, 2012, 33:2403-2414) ** Part of the Death case

Annuloplasty: Significant Reduction in Septo Lateral (A-P) Dimension 30% average reduction in A-P *P<0.01 37±4 (29-46) 26±4 (18-35)

30% average reduction in A-P Annular Reconstruction by Significant Reduction in Septo Lateral (A-P) Dimension 30% average reduction in A-P *P<0.01 37±4 (29-46) 26±4 (18-35)

Septo-Lateral (A-P) Dimension (mm) over time

91% patients with MR≤2+ At 12 Months By Core Lab* at Discharge 84% MR ≤ 2+ at 1 Month 91% MR ≤ 2+ at 6 Months 90% MR ≤ 2+ at 12 Months *Dr. Paul Grayburn – Baylor University

Annuloplasty: Significant Reduction in Septo Lateral (A-P) Dimension 30% average reduction in A-P *P<0.01 37±4 (29-46) 26±4 (18-35)

Cardioband: Functional Improvement at 12 Months 6MWT P<0.05 MLHFQ P<0.01 NYHA Class P<0.01 343 41 II I 68% NYHA I/II Meters Walked MLHFQ Score % of population II 272 20 III III Baseline 12 Months Baseline 12 Months N = 15 N = 20 N = 23

The complementary role of transcatheter techniques annuloplasty mitraclip replacement Stand-alone Annuloplasty: early treatment FMR Stand-alone Mitraclip: FMR with asymmetric tethering (IMR) Combined Annuloplasty and MitraClip: Advanced FMR MV Replacement: Advanced FMR (Adapted from F Maisano)

Future Directions and Dilemmas COAPT- enrollment increasing Will it create a new standard Need more efficient trials COAPT light? Achievable but clinically relevant endpoints MR reduction not enough Heart Failure Hospitalizations, Exercise Capacity, QoL, Actigraphy Repair vs. Replacement Patient selection